Novo Nordisk マネジメント

マネジメント基準チェック /34

Novo Nordiskの CEO はLars Jorgensenで、 Jan2017年に任命され、の在任期間は 7.83年です。は、会社の株式の0.002%を直接所有しており、その価値は€ 8.77M 。経営陣と取締役会の平均在任期間はそれぞれ3.8年と6.7年です。

主要情報

Lars Jorgensen

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	7.8yrs
CEOの所有権	0.002%
経営陣の平均在職期間	3.8yrs
取締役会の平均在任期間	6.7yrs

経営陣の近況

Recent updates

CEO報酬分析

Novo Nordisk の収益と比較して、Lars Jorgensen の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	DKK 95b
Jun 30 2024	n/a	n/a	DKK 90b
Mar 31 2024	n/a	n/a	DKK 89b
Dec 31 2023	n/a	n/a	DKK 84b
Sep 30 2023	n/a	n/a	DKK 75b
Jun 30 2023	n/a	n/a	DKK 67b
Mar 31 2023	n/a	n/a	DKK 61b
Dec 31 2022	DKK 60m	DKK 17m	DKK 56b
Sep 30 2022	n/a	n/a	DKK 53b
Jun 30 2022	n/a	n/a	DKK 51b
Mar 31 2022	n/a	n/a	DKK 49b
Dec 31 2021	DKK 58m	DKK 17m	DKK 48b
Sep 30 2021	n/a	n/a	DKK 46b
Jun 30 2021	n/a	n/a	DKK 44b
Mar 31 2021	n/a	n/a	DKK 43b
Dec 31 2020	DKK 57m	DKK 14m	DKK 42b
Sep 30 2020	n/a	n/a	DKK 42b
Jun 30 2020	n/a	n/a	DKK 41b
Mar 31 2020	n/a	n/a	DKK 40b
Dec 31 2019	DKK 55m	DKK 14m	DKK 39b
Sep 30 2019	n/a	n/a	DKK 39b
Jun 30 2019	n/a	n/a	DKK 38b
Mar 31 2019	n/a	n/a	DKK 38b
Dec 31 2018	DKK 41m	DKK 11m	DKK 39b
Sep 30 2018	n/a	n/a	DKK 38b
Jun 30 2018	n/a	n/a	DKK 39b
Mar 31 2018	n/a	n/a	DKK 39b
Dec 31 2017	DKK 32m	DKK 9m	DKK 38b

報酬と市場: Larsの総報酬がAustrian市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。

報酬と収益: Larsの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Lars Jorgensen (58 yo)

7.8yrs

在職期間

DKK 60,100,000

報酬

Mr. Lars Fruergaard Jorgensen serves as Director at Danmarks Nationalbank since April 2024. He has been Chief Executive Officer and President of Novo Nordisk A/S since January 2017and serves as its Member...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Lars Jorgensen	President	7.8yrs	DKK 60.10m	0.0021% € 8.8m
Karsten Knudsen	Executive VP	6.8yrs	DKK 21.50m	0.000010% € 42.0k
Henrik Wulff	Executive VP of Product Supply	no data	DKK 22.00m	0.000060% € 251.7k
Camilla Sylvest	Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board	no data	DKK 21.30m	データなし
Martin Lange	Executive VP of Development & Member of the Management Board	3.8yrs	DKK 20.90m	データなし
Marcus Schindler	EVP of Research & Early Development	3.7yrs	DKK 20.90m	データなし
Maziar Doustdar	Executive VP of International Operations & Member of the Management Board	no data	データなし	0.0011% € 4.7m
Douglas Langa	Executive VP of North America Operations & Member of Management Board	no data	データなし	データなし
Ludovic Helfgott	Executive VP	no data	データなし	データなし
Tania Sabroe	Executive VP of Global People & Organisation and Member of Management Board	1.7yrs	データなし	データなし
David Moore	Executive VP of Corporate Development & Member of Management Board	1.7yrs	データなし	データなし
Jacob Martin Rode	Head of Investor Relations	no data	データなし	データなし

3.8yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: NNO2の経営陣は経験豊富であると考えられます ( 3.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Sylvie Gregoire	Independent Director	9.7yrs	DKK 1.80m	データなし
Helge Lund	Independent Chairman of the Board	7.7yrs	DKK 3.10m	データなし
Henrik Poulsen	Vice Chairman of the Board	3.7yrs	DKK 2.00m	データなし
Laurence Debroux	Independent Director	5.7yrs	DKK 2.00m	データなし
Martin MacKay	Independent Director	6.7yrs	DKK 1.70m	データなし
Andreas Fibig	Independent Director	6.7yrs	DKK 1.40m	データなし
Kasim Kutay	Non-Independent Director	7.7yrs	DKK 1.20m	データなし
Christina Law	Independent Director	2.7yrs	DKK 1.30m	データなし
Liselotte Hyveled	Employee Representative Director	2.7yrs	DKK 800.00k	0% € 0
Mette Jensen	Employee Non-Independent Representative Director	6.7yrs	DKK 1.20m	データなし
Thomas Rantzau	Employee Representative Non-Independent Director	6.8yrs	DKK 1.00m	データなし
Elisabeth Christensen	Employee Representative Director	2.7yrs	DKK 800.00k	データなし

6.7yrs

平均在職期間

58.5yo

平均年齢

経験豊富なボード: NNO2の取締役会は経験豊富であると考えられます ( 6.7年の平均在任期間)。

Novo Nordisk マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Employee Representative Director recently sold €1.0m worth of stock

Key Executive recently sold €6.7m worth of stock

President recently sold €19m worth of stock

Insider recently sold €1.4m worth of stock

Recent updates

Novo Nordisk A/S to Report Q2, 2025 Results on Aug 06, 2025

Third quarter 2024 earnings released: EPS: kr.6.13 (vs kr.5.02 in 3Q 2023)

Novo Nordisk A/S Provides Earnings Guidance for 2024

Novo Nordisk A/S Announces Results from Part 1 of the Ongoing ESSence Trial

Now 22% undervalued after recent price drop

Novo Nordisk A/S Announces Monlunabant Phase 2A Trial in Obesity Successfully Completed

Aragen Life Sciences Reportedly Plans to Dilute About 10% Stake

Employee Representative Director recently sold €1.0m worth of stock

Second quarter 2024 earnings released: EPS: kr.4.50 (vs kr.4.33 in 2Q 2023)

New minor risk - Share price stability

Novo Nordisk A/S Decides to Pay Interim Dividend for 2024, Payable on 19 August 2024 for A and B Shares and 26 August 2024 for ADRs

European Regulatory Authority Adopts A Positive Opinion for an Update of the Wegovy® Label to Reflect Risk Reduction of Major Adverse Cardiovascular Events

Novo Nordisk Receives Complete Response Letter in the US for Once-Weekly Basal Insulin Icodec

Key Executive recently sold €6.7m worth of stock

Novo Nordisk Announces Wegovy (Semaglutide Injection) Available in Canada

First quarter 2024 earnings released: EPS: kr.5.70 (vs kr.4.40 in 1Q 2023)

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Final dividend of kr.6.40 announced

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

President recently sold €19m worth of stock

Full year 2023 earnings released: EPS: kr.18.67 (vs kr.12.26 in FY 2022)

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.

Novo Nordisk A/S Announces Topline Results from the Combine 3 Phase 3A Trial of Once-Weekly IcoSema

Insider recently sold €1.4m worth of stock

Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024

Third quarter 2023 earnings released

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk to Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, Flow, Based on Interim Analysis

Novo Nordisk A/S (CPSE:NOVO B) acquired Embark Biotech ApS for approximately €470 million.

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovations and others for $1 billion.

Second quarter 2023 earnings released: EPS: kr.8.65 (vs kr.5.87 in 2Q 2022)

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 21%

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire a 64.4% stake in Biocorp Production (ENXTPA:ALCOR) for €99.1 million.

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34